Long-term Outcome of Kidney Retransplantation in Comparison With First Kidney Transplantation: A Report From the Thai Transplantation Registry

• Published in: Transplantation proceedings Vol. 45; no. 4; pp. 1427 - 1430
• Main Authors: Ingsathit, A, Kantachuvesiri, S, Rattanasiri, S, Avihingsanon, Y, Premasathian, N, Pongskul, C, Jittikanont, S, Lumpaopong, A, Sumethkul, V
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.05.2013
• Subjects: Adult; Female; Humans; Immunosuppressive Agents - therapeutic use; Kidney Transplantation; Living Donors; Male; Middle Aged; Registries; Reoperation; Surgery; Thailand; Treatment Outcome; Thailand
• ISSN: 0041-1345; 1873-2623
• DOI: 10.1016/j.transproceed.2012.08.029

Abstract Introduction Kidney retransplantation is a high-risk procedure that is increasingly performed because of previous graft failure. The aim of this study was to determine the long-term outcomes of kidney retransplantations compared with first kidney transplantations under the current era of immunosuppression. Methods Since the first retransplantation in Thailand was performed in 1993, this study included all consecutive cases registered in the Thai Transplantation Registry database from January 1993 to December 2011. A total of 3337 kidney transplantations were available for the analysis. Graft loss was defined as a return to dialysis or graft removal. Death with a functioning graft was censored. Results Of 3337 kidney transplantations during the study period, 113 were second and 3 were third transplantations. Among these 116 retransplantations, the most common identified causes of end-stage renal disease were chronic glomerulonephritis (38.8%), followed by hypertensive nephropathy (13.0%), diabetic nephropathy (6.0%), and lupus nephritis (1.7%). The retransplantation recipients were older (mean age, 46.2 ± 12.8 years) than the first transplantation group (mean age, 42.2 ± 12.8 years). The proportion of living-related kidney transplantations and male sex were similar between first and retransplantation recipients. Fourteen percent of retransplantation recipients showed high immunologic risk as defined by current panel reactive antibodies ≥30% compared with 3% of those in the first transplantation group ( P < .001). The percentages of induction therapy with antithymocyte globulin and anti–interleukin-2 antibody in the retransplantation and first transplantation groups were 18.3% versus 4.3% and 60.0% versus 32.6%, respectively. The graft survival rates (95% confidence interval [CI]) at 1, 5, and 10 years were 88.6% (80.7–93.3), 87.3% (79.1–92.5), and 74.4% (53.7–86.9) among retransplantation, versus 95.0% (94.1–95.7), 87.0% (85.5–88.5), and 70.7% (67.4–73.8) among first transplantation groups, respectively ( P = .63). Patient survival rates were not different between first and retransplantation groups ( P = .42). The leading cause of graft loss in the retransplantation group was chronic allograft nephropathy (22%), whereas infection (57%) was the major cause of death in this group. Conclusion The 10-year patient and graft survival rates of kidney retransplantation were acceptable. The combination of induction therapy with a calcineurin inhibitor and a mycophenolate mofetil/mychophenolic acid–based regimen lead to outcomes comparable to first kidney transplantations among our cohort of 3337 patients.